Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Lerochol Coverage & Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PHAR.768

    Clinical Policy: Lerodalcibep-liga (Lerochol)

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.768 alerts

    Get alerted when Policy CP.PHAR.768 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines medical necessity and prior authorization criteria for lerodalcibep-liga (Lerochol) for adults with hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) across QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Lerodalcibep-liga (Lerochol)
    Policy CodePolicy CP.PHAR.768
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit office chart notes, lab results, and documentation of prior therapy and recent LDL-C to support authorization.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    300 mgMonthly dose
    ≤300Max allowed dose/mo
    DefinedLDL-C thresholds
    6–12 moApproval duration
    300 mg/1.2 mLProduct strength

    Coverage Criteria for Lerodalcibep-liga (Lerochol)

    Initial Therapy

    Covered when ALL of the following are met for Initial Approval — Primary Hypercholesterolemia (including HeFH) and CV event risk reduction:

    Initial Approval - Primary Hypercholesterolemia (including HeFH) and CV event risk reduction: 1) Diagnosis: one of the following: a) HeFH, and both: i) Baseline LDL-C (prior to any lipid‑lowering pharmacologic therapy): if age < 20 years ≥ 160 mg/dL; if age ≥ 20 years ≥ 190 mg/dL; and ii) HeFH confirmed by WHO/Dutch Lipid Network score > 8 OR definite Simon Broome criteria (see Appendix D). b) Primary hypercholesterolemia that is not HeFH, and both: i) Documentation of genetically mediated primary hypercholesterolemia OR ii) Baseline LDL-C (prior to any lipid‑lowering pharmacologic therapy) ≥ 190 mg/dL, and secondary causes of hypercholesterolemia have been ruled out (e.g., poor diet, hypothyroidism, obstructive liver disease, nephrosis, medications contributing to lipids). c) Increased CV risk from established ASCVD (examples: acute coronary syndromes, clinically significant CHD by testing, coronary or other arterial revascularization, myocardial infarction, peripheral arterial disease of atherosclerotic origin, stable/unstable angina, stroke or TIA).

    See Appendix D for diagnostic scoring and Appendix F/G for contraindication and intolerance definitions.

    Continuation Therapy

    Covered when ALL of the following are met for Continued Therapy — Primary Hypercholesterolemia (including HeFH) and CV event risk reduction:

    Continued Therapy: 1) Member is currently receiving the medication via the Centene benefit or previously met initial approval criteria, or continuity of care applies per state rules. 2) If statin tolerant: documentation of adherence to a statin at the maximally tolerated dose. 3) Member is responding to therapy as evidenced by LDL‑C reduction shown in lab results within the last 3 months. 4) Treatment plan excludes coadministration with Leqvio, Juxtapid, Repatha, or Praluent. 5) If requesting a dose increase, new dose does not exceed 300 mg per month.

    Approval durations: Medicaid/HIM 12 months; Commercial 6 months or to renewal date.

    Non‑FDA approved indications not specifically addressed in this policy are not authorized for coverage unless the provider supplies sufficient clinical documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid).

    Contraindications relevant to background statin therapy include: decompensated liver disease (eg, jaundice, ascites, variceal bleeding, encephalopathy); laboratory‑confirmed acute liver injury or statin‑related rhabdomyolysis; pregnancy, actively trying to become pregnant, or nursing; and immune‑mediated hypersensitivity to the statin class (documented allergic reaction to at least two different statins). For ezetimibe, contraindications include moderate or severe hepatic impairment (Child‑Pugh B or C) and documented hypersensitivity to ezetimibe.

    When state Medicaid coverage provisions conflict with this clinical policy, the state Medicaid provisions take precedence. Providers should consult the applicable state Medicaid manual for any state‑specific coverage rules that supersede this policy.

    Coding and LDL Thresholds

    HCPCS Codes referencedHCPCS
    J3590Unclassified biologics.
    C9399Unclassified drugs or biologicals.
    inv-07: LDL-C thresholds — Baseline and recent LDL-C thresholds and timing references
    Baseline LDL-C for HeFH (age <20)≥ 160 mg/dL (baseline, prior to any lipid-lowering therapy)
    Baseline LDL-C for HeFH (age ≥20)≥ 190 mg/dL (baseline, prior to any lipid-lowering therapy)
    Recent LDL-C (within 60 days) — ASCVD≥ 70 mg/dL (or ≥ 55 mg/dL if very high risk)
    Recent LDL-C (within 60 days) — severe primary hypercholesterolemia/HeFH≥ 100 mg/dL
    inv-08: LDL-C bands for FH scoring — LDL-C ≥ 330; 250-329; 190-249; 155-189 mg/dL
    LDL-C ≥ 330 mg/dLAssigned points in Dutch Lipid Clinic Network scoring (highest cholesterol level category)

    Provider Actions, Documentation, and Authorization Requirements

    Prior Authorization

    Prior authorization: preferred PCSK9 trial required

    Prior authorization requests must include evidence that the member failed an 8-week trial of a preferred PCSK9 inhibitor at maximally indicated doses when applicable; Illinois HIM requests are exempt from this step therapy requirement per IL HB 5395 (effective 1/1/2026).

    • Failure defined as intolerance or inadequate response after an 8-week trial at up to maximally indicated doses.
    • State law exception: IL HB 5395 removes the step therapy requirement for Illinois HIM requests.
    Prior Authorization

    Confirm labeled dose and product strength on PA

    Prior authorization and approval should reflect the labeled dosing regimen of 300 mg subcutaneously once monthly and the product presentation of a single-use pre-filled syringe 300 mg/1.2 mL.

    • Labeled dosing: 300 mg SC monthly.
    • Product supplied as single-use pre-filled syringe 300 mg/1.2 mL.

    Background on Lerodalcibep-liga (Lerochol)

    Lerodalcibep‑liga (Lerochol) is a PCSK9‑targeted therapy indicated as an adjunct to diet and exercise to reduce LDL‑C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The policy aligns use of Lerochol with background statin and ezetimibe therapy and specifies the labeled dosing of 300 mg subcutaneously once monthly and the supplied presentation as a single‑use pre‑filled syringe (300 mg/1.2 mL).

    Definitions and Product Presentation

    inv-23: LDL-C — Definition of low density lipoprotein cholesterol.
    TermLDL-C: low density lipoprotein cholesterol
    Use in policyReferenced for eligibility thresholds and monitoring (baseline and recent values)
    AbbreviationLDL-C is used throughout appendices and criteria as the primary lipid measure
    inv-24: HeFH — Definition of heterozygous familial hypercholesterolemia.
    TermHeFH: heterozygous familial hypercholesterolemia
    Diagnostic contextHeFH diagnosis required specific baseline LDL-C thresholds and confirmation by scoring or Simon Broome criteria

    Initial Therapy Criteria and Dosing

    Initial Therapy — Initial approval requires meeting diagnostic, specialist prescriber, age, prior therapy, statin/ezetimibe, LDL-C, drug interaction, and dosing conditions.

    Initial approval requires meeting diagnostic, specialist prescriber, age, prior therapy, statin/ezetimibe, LDL‑C, drug interaction, and dosing conditions.

    Initial Therapy - Lerochol specific requirements: 1) Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist. 2) Age ≥ 18 years. 3) Failure of an 8‑week trial of a preferred PCSK9 inhibitor at maximally indicated doses, if applicable, unless contraindicated or intolerant (note: Illinois HIM requests are exempt per IL HB 5395). 4) If on statin: Lerochol prescribed with a statin at maximally tolerated dose AND member adherent for at least the last 8 weeks to maximally tolerated statin regimen (see Appendix E for intensity definitions and examples of prior high‑intensity use or documented intolerance). 5) If not on statin: documented statin contraindication per Appendix F OR statin intolerance with at least two statin trials (one hydrophilic) and appropriate rechallenge documentation. 6) Member adherent to concurrent ezetimibe with a statin for at least 4 months unless contraindicated or intolerant. 7) Recent LDL‑C (within 60 days) meeting thresholds: if ASCVD ≥ 70 mg/dL (or ≥ 55 mg/dL if very high risk per Appendix I); if severe primary hypercholesterolemia (including HeFH) ≥ 100 mg/dL. 8) Treatment plan must not include coadministration with Leqvio, Juxtapid, Repatha, or Praluent. 9) Requested dose must not exceed 300 mg per month (maximum dose).

    Providers must submit supporting chart notes and labs (recent LDL‑C within 60 days), and documentation for prior therapies, HeFH diagnostic criteria, and statin/ezetimibe adherence.

    Continuation Criteria

    Continued Therapy

    Continuation criteria require evidence of benefit and adherence.

    Continued Therapy - evidence and adherence: 1) Member currently receiving medication via benefit or previously met initial criteria (or continuity of care applies). 2) If statin tolerant: documentation of adherence to a statin at the maximally tolerated dose. 3) Member demonstrates clinical response: LDL‑C reduction on labs within the last 3 months compared to baseline since initiation of Lerochol. 4) Treatment plan excludes coadministration with Leqvio, Juxtapid, Repatha, or Praluent. 5) Dose maintained ≤ 300 mg per month if no increase is requested.

    Approval duration varies by line of business (Medicaid/HIM 12 months; Commercial 6 months or to renewal).

    Concomitant therapy — Guidance for ongoing therapy and maintaining statin if tolerated.

    Guidance for ongoing therapy and maintaining background lipid‑lowering treatment.

    Concomitant therapy: 1) Patients should remain on concomitant statin therapy if tolerated due to established long‑term cardiovascular benefits. 2) If statin tolerant: continue maximally tolerated statin per Appendix E intensity definitions; document adherence. 3) If statin intolerant or contraindicated: documentation per Appendix F/G is required and prior attempts/rechallenge per initial criteria must be documented. 4) Maintain concomitant ezetimibe when required by initial approval unless contraindicated or intolerant.

    Step Therapy Requirements

    StepRequirementNotes / Exceptions
    1Trial of a preferred PCSK9 inhibitor for 8 weeks at maximally indicated doses prior to LerocholFor Illinois HIM requests, the step therapy requirement does not apply per IL HB 5395 (effective 1/1/2026). Prior authorization may be required for PCSK9 inhibitors.
    StepRequirementNotes
    1Lerochol must be prescribed in conjunction with a statin at the maximally tolerated dose when the member is statin tolerant; document adherence for at least the last 8 weeksPatients should remain on concomitant statin therapy if tolerated due to established long‑term cardiovascular benefits. See Appendices for high- and moderate-intensity statin dose examples.

    Quantity Limits and Dosing Caps

    inv-36: Lerodalcibep-liga (Lerochol) — Quantity limit value 300.
    Quantity limit value300 (mg per month)
    Applies toLerodalcibep-liga (Lerochol)
    RationaleMatches labeled monthly dose and maximum allowed by policy
    inv-37: Lerodalcibep-liga (Lerochol) — 300 mg monthly limit (explicit).
    Monthly limit300 mg per month (standard/maximum)
    Unit equivalenceOne 300 mg/1.2 mL pre-filled syringe equals the monthly allowed quantity
    Policy constraint

    Site of Care and Administration

    Note

    Product presentation: single‑use 300 mg/1.2 mL pre-filled syringe

    The product is supplied as a single‑use pre-filled syringe (300 mg/1.2 mL) intended for subcutaneous administration; documentation of the supplied presentation may be included with prior authorization.

    Note

    Site of care: pre-filled syringe; setting not restricted

    Product supply is a single‑use pre-filled syringe suitable for subcutaneous administration; the policy does not restrict site of care in this section.

    Policy Summary
    PayerQualChoice
    PolicyClinical Policy: Lerodalcibep-liga (Lerochol)
    Policy CodePolicy CP.PHAR.768
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit office chart notes, lab results, and documentation of prior therapy and recent LDL-C to support authorization.
    SourceLink
    On This Page
    Coverage Criteria for Lerodalcibep-liga (Lerochol)Coding and LDL ThresholdsProvider Actions, Documentation, and Authorization RequirementsBackground on Lerodalcibep-liga (Lerochol)Definitions and Product PresentationInitial Therapy Criteria and DosingContinuation CriteriaStep Therapy RequirementsQuantity Limits and Dosing CapsSite of Care and Administration
    LDL-C 250–329 mg/dLAssigned points in Dutch Lipid Clinic Network scoring
    LDL-C 190–249 mg/dLAssigned points in Dutch Lipid Clinic Network scoring
    LDL-C 155–189 mg/dLAssigned points in Dutch Lipid Clinic Network scoring
    inv-09: Dose — 300 mg SC monthly
    Standard dose300 mg subcutaneously once monthly
    Maximum monthly doseDoes not exceed 300 mg per month
    Indication contextDosing regimen for hypercholesterolemia including HeFH
    Billing Rule

    Obtain prior authorization and code appropriately (J3590, C9399)

    When requesting prior authorization and when submitting claims, reference the HCPCS listings in the policy; the document notes J3590 and C9399 as the codes referenced, and providers should obtain prior authorization per payer processes when billing these codes.

    • HCPCS codes referenced in this policy: J3590 (Unclassified biologics) and C9399 (Unclassified drugs or biologicals).
    • Inclusion/exclusion of codes here does not guarantee coverage — verify current coding guidance before claim submission.
    Step Therapy

    Step therapy and background lipid‑lowering therapy required

    Approval requires failure of a preferred PCSK9 inhibitor trial and documentation of adherence to maximally tolerated statin (or documented statin contraindication/intolerance); ezetimibe adherence when used concomitantly is also required per initial criteria.

    • 8-week trial of a preferred PCSK9 inhibitor at maximally indicated doses unless contraindicated or intolerant.
    • If on statin: Lerochol must be prescribed with a statin at maximally tolerated dose and member adherent for at least the last 8 weeks.
    • Member must have been adherent to ezetimibe used with a statin for at least the last 4 months unless contraindicated or intolerant.
    Step Therapy

    Document concomitant maximally tolerated statin therapy

    Document concomitant maximally tolerated statin therapy when applicable; patients should remain on statin therapy if tolerated and statin intensity classifications (high/moderate) are provided in the appendices.

    • If statin tolerant, Lerochol must be prescribed with a statin at the maximally tolerated dose (see Appendix E for high-intensity and Appendix for moderate-intensity examples).
    • Patients should remain on concomitant statin therapy if tolerated due to long-term cardiovascular benefits.
    Note

    No other explicit step therapy steps listed here

    The policy notes no additional explicit step therapy requirements in the surrounding document window beyond the stated preferred PCSK9 trial and statin/ezetimibe background therapy; check state exceptions (e.g., IL HB 5395) for applicability.

    • No other explicit step therapy steps are listed in this section beyond the preferred PCSK9 trial and statin/ezetimibe requirements.
    • Verify state-specific exceptions such as Illinois HIM under IL HB 5395.
    Documentation Required

    Submit clinical documentation and recent LDL‑C

    Providers must submit office chart notes, laboratory results, or other clinical information supporting that the member has met all approval criteria, including a recent LDL‑C measured within the last 60 days and documentation of prior therapy trials and statin/ezetimibe adherence.

    • Include recent LDL‑C within 60 days demonstrating threshold criteria.
    • Include documentation of prior PCSK9 trial, statin adherence/intolerance, and ezetimibe use where applicable.
    Documentation Required

    Provide HeFH diagnostic documentation per formal criteria

    For HeFH diagnoses, include documentation per the Dutch Lipid Clinic Network or Simon Broome criteria — e.g., scoring across family history, clinical history, physical exam, cholesterol levels (LDL‑C bands) and DNA analysis when available — and record family history details as applicable.

    • Use Dutch Lipid Clinic Network scoring (choose highest score in each category and sum) with LDL‑C bands (e.g., ≥330; 250–329; 190–249; 155–189 mg/dL).
    • Simon Broome criteria: elevated total cholesterol or LDL plus tendinous xanthomas or DNA evidence of LDL receptor mutation.
    Note

    Consult prescribing information and cited guidelines

    Consult the policy references and the Lerochol Prescribing Information and referenced guideline documents for clinical details and prescribing requirements; these materials are cited in the policy.

    • Key reference: Lerochol Prescribing Information (LIB Therapeutics, Dec 2025).
    • Additional guideline references provided (ACC/AHA, NLA, etc.) for clinical guidance.
    Denial Risk

    Insufficient documentation or off‑label requests risk denial

    Failure to provide required documentation that the member meets all approval criteria, or requests for non‑FDA indicated uses without supporting evidence per off‑label use policies, may result in denial of the request.

    • Non‑FDA indications are not authorized unless sufficient documentation per off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) is provided.
    • Lack of supporting clinical documentation for criteria may lead to denial.
    Denial Risk

    Dose exceedance (>300 mg/month) will not conform to policy

    Requests for doses above the policy maximum would not conform to the stated dosing regimen; the maximum allowed dose is 300 mg per month.

    • Maximum dose per policy: 300 mg/month. Requests exceeding this (greater than 300 mg/month) are nonconforming.
    Billing Rule

    Coding inclusion/exclusion does not guarantee coverage — verify guidance

    The policy includes HCPCS codes for informational purposes only and warns that inclusion or exclusion of any codes does not guarantee coverage; providers should verify current coding guidance before submitting claims.

    • Codes referenced (informational): J3590 and C9399.
    • Verify up‑to‑date professional coding guidance prior to claim submission.
    Policy role
    Included as an indication for Lerochol in initial and continuation criteria
    inv-25: Dutch Lipid Clinic Network criteria — Structured scoring to categorize FH probability.
    ScopeStructured scoring across family history, clinical history, physical exam, cholesterol levels, and DNA analysis
    Scoring instructionChoose the highest score from each category and sum for total score
    Cholesterol bandsIncludes LDL-C categories (≥330; 250–329; 190–249; 155–189 mg/dL) used to assign points
    inv-26: Simon Broome Definite FH — Simon Broome criteria summary.
    Definite FH (Simon Broome)Requires elevated total cholesterol or LDL plus either tendinous xanthomas in patient/relative or DNA evidence of an LDL receptor mutation or familial defective apoB100
    Cholesterol thresholdsAdults: total cholesterol >290 mg/dL or LDL >190 mg/dL (pre-treatment or highest on treatment)
    Supporting findingsTendinous xanthomas in patient or relative OR DNA-based evidence
    inv-27: 300 mg SC monthly — Dosing regimen (definition entry).
    DefinitionAdministration of 300 mg subcutaneously once monthly
    Therapeutic contextLabeled dosing for treatment of hypercholesterolemia including HeFH
    MaximumMaximum monthly dose = 300 mg
    inv-28: Single-use pre-filled syringe 300 mg/1.2 mL — Product presentation.
    PresentationSingle-use pre-filled syringe containing 300 mg in 1.2 mL
    RouteSupplied for subcutaneous administration
    Use noteProduct availability noted in Appendices; aligns with dosing (one syringe = 300 mg)

    Initial Therapy — Labeled initial dosing.

    Labeled initial dosing.

    Initial dosing: Administer 300 mg subcutaneously once monthly.

    Product presentation: single‑use prefilled syringe 300 mg/1.2 mL (see product information).

    Initial/Standard Dosing

    Dosing for initial and routine therapy.

    Standard dosing: Administer 300 mg subcutaneously every month.300 mg monthly

    Maximum monthly dose = 300 mg.

    Appendices provide statin intensity definitions, contraindications, and SAMS diagnostic/rechallenge guidance.

    Dose requests exceeding 300 mg/month do not conform to dosing regimen
    inv-38: Lerodalcibep-liga (Lerochol) — 300 mg quantity/limit duplication entry.
    Quantity/limit entry300 mg per month (policy lists limit as 300 mg; product supplied as 300 mg syringe)
    Duplication noteMultiple entries in quantity limits reflect same 300 mg/month cap in policy appendices
    Billing implicationPrior authorization and claims should reflect single 300 mg syringe per monthly fill when applicable